Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.

Creative Commons License

Cakirca M., Karatoprak C., Zorlu M., Kiskac M., Kanat M., CIKRIKCIOGLU M. A., ...Daha Fazla

Drug design, development and therapy, cilt.8, ss.239-43, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8
  • Basım Tarihi: 2014
  • Doi Numarası: 10.2147/dddt.s52545
  • Dergi Adı: Drug design, development and therapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.239-43
  • Anahtar Kelimeler: asymmetric dimethylarginine (ADMA), dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, type 2 diabetes mellitus, GLUCAGON-LIKE PEPTIDE-1, MYOCARDIAL-INFARCTION, HEART-FAILURE, DYSFUNCTION, INHIBITION, RATS
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Bezmiâlem Vakıf Üniversitesi Adresli: Evet

Özet

Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.